Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out the effects of adding B lymphocyte
modulating agents in patients at risk for rejection receiving an anti-rejection
(immunosuppressive) regimen of Thymoglobulin® induction with Prograf®, Cellcept® and
corticosteroid therapy.
Phase:
Phase 4
Details
Lead Sponsor:
University of Cincinnati
Collaborators:
Genzyme, a Sanofi Company Millennium Pharmaceuticals, Inc.